Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
4.845
+0.415 (+9.37%)
Streaming Delayed Price
Updated: 3:08 PM EST, Feb 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
↗
October 17, 2022
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
Via
Benzinga
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
↗
October 06, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
↗
October 06, 2022
Upgrades
Via
Benzinga
Recap: Myriad Genetics Q1 Earnings
↗
May 05, 2022
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For November 2, 2021
↗
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
Is Illumina Still the Gamechanger in Genomics Sequencing?
October 04, 2022
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Via
MarketBeat
Topics
Earnings
Economy
Lawsuit
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
September 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
July 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
↗
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
What's Up With Myriad Genetics Shares Trading Higher Tuesday?
↗
August 03, 2021
Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading hig...
Via
Benzinga
Can Artificial Intelligence Predict Our Future Health?
↗
July 05, 2022
Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
June 01, 2022
On Wednesday, 73 stocks hit new 52-week lows.
Via
Benzinga
77 Biggest Movers From Yesterday
↗
June 01, 2022
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...
Via
Benzinga
40 Stocks Moving In Tuesday's Mid-Day Session
↗
May 31, 2022
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare...
Via
Benzinga
Myriad Genetics's Earnings: A Preview
↗
May 04, 2022
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad...
Via
Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
↗
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
↗
March 14, 2022
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-...
Via
Benzinga
Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript
↗
November 02, 2021
MYGN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
↗
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Myriad Genetics Insider Sold Over $None In Company Stock
↗
September 28, 2021
Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4 filing from...
Via
Benzinga
Topics
Regulatory Compliance
4 Stocks Insiders Are Buying
↗
August 09, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
75 Biggest Movers From Yesterday
↗
August 04, 2021
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a...
Via
Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
↗
August 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Myriad Genetics, inc (MYGN) Q2 2021 Earnings Call Transcript
↗
August 03, 2021
MYGN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
48 Stocks Moving In Tuesday's Mid-Day Session
↗
August 03, 2021
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures...
Via
Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
↗
August 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Earnings Scheduled For August 3, 2021
↗
August 03, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
↗
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
↗
July 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.